

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6066754

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AERPIO THERAPEUTICS LLC	04/13/2020

RECEIVING PARTY DATA

Name:	AERPIO PHARMACEUTICALS, INC.
Street Address:	9987 CARVER ROAD, SUITE 420
City:	CINCINNATI
State/Country:	OHIO
Postal Code:	45242

PROPERTY NUMBERS Total: 97

Property Type	Number
Application Number:	60413547
Application Number:	12610843
Application Number:	60790506
Application Number:	60798896
Application Number:	15894442
Application Number:	13958990
Application Number:	60816730
Application Number:	60816731
Application Number:	60816825
Application Number:	15705639
Application Number:	12558169
Application Number:	61144022
Application Number:	61184986
Application Number:	12677512
Application Number:	14075809
Application Number:	15443353
Application Number:	13968269
Application Number:	61223260
Application Number:	15913392
Application Number:	15796293

PATENT

Property Type	Number
Application Number:	61390899
Application Number:	13253397
Application Number:	14300385
Application Number:	15462326
Application Number:	61546708
Application Number:	14627463
Application Number:	61546697
Application Number:	61546748
Application Number:	13652203
Application Number:	16168060
Application Number:	61792679
Application Number:	61792868
Application Number:	61882048
Application Number:	61882056
Application Number:	61934570
Application Number:	14214413
Application Number:	15099161
Application Number:	15443622
Application Number:	15098955
Application Number:	15958346
Application Number:	15958355
Application Number:	15958358
Application Number:	15969109
Application Number:	16257287
Application Number:	61953680
Application Number:	15972863
Application Number:	15365186
Application Number:	62034695
Application Number:	62190871
Application Number:	62019002
Application Number:	62361703
Application Number:	62054752
Application Number:	14862948
Application Number:	15815097
Application Number:	62222481
Application Number:	15273068
Application Number:	62364381
Application Number:	62377072

Property Type	Number
Application Number:	16180850
Application Number:	16180854
Application Number:	62635102
Application Number:	62790646
Application Number:	16284349
Patent Number:	7226755
Patent Number:	7507568
Patent Number:	7632862
Patent Number:	7769575
Patent Number:	9926367
Patent Number:	7973142
Patent Number:	8524235
Patent Number:	7622593
Patent Number:	7795444
Patent Number:	7589212
Patent Number:	8258311
Patent Number:	8338615
Patent Number:	8946232
Patent Number:	8895563
Patent Number:	8329916
Patent Number:	9126958
Patent Number:	9284285
Patent Number:	9795594
Patent Number:	8106078
Patent Number:	8188125
Patent Number:	8846685
Patent Number:	9096555
Patent Number:	8883832
Patent Number:	9174950
Patent Number:	9949956
Patent Number:	8569348
Patent Number:	8999325
Patent Number:	10329357
Patent Number:	10150811
Patent Number:	9440963
Patent Number:	10220048
Patent Number:	9994560
Patent Number:	9539245

Property Type	Number
Patent Number:	10253094

CORRESPONDENCE DATA

Fax Number: (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: patentdocket@wsgr.com, rgallo@wsgr.com

Correspondent Name: WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304-1050

ATTORNEY DOCKET NUMBER: 45725

NAME OF SUBMITTER: TRISHA AGRAWAL

SIGNATURE: /Trisha Agrawal/

DATE SIGNED: 04/17/2020

Total Attachments: 4

source=Aerpio 45725-700 CORP to CORP executed Assignment#page1.tif

source=Aerpio 45725-700 CORP to CORP executed Assignment#page2.tif

source=Aerpio 45725-700 CORP to CORP executed Assignment#page3.tif

source=Aerpio 45725-700 CORP to CORP executed Assignment#page4.tif

WHEREAS, Aerpio Therapeutics LLC (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

[SEE ATTACHMENT A]

WHEREAS, Aerpio Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at at 9987 Carver Road, Suite 420, Cincinnati, OH 45243, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Inventions, and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

See page 2

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

Date: April 13, 2020

ASSIGNOR
By: Joseph A. Rowan

Name: Aerpio Therapeutics LLC

Title: President

RECEIVED AND AGREED TO BY ASSIGNEE:

Date: April 13, 2020

By: Joseph A. Rowan

Name: Aerpio Pharmaceuticals, Inc.

Title: President

ATTACHMENT A

<u>Application Number</u>	<u>Filing Date</u>	<u>Patent Number</u>
60/413,547	25-Sep-2002	
10/633,742	04-Aug-2003	7,226,755
10/634,027	04-Aug-2003	7,507,568
11/787,535	17-Apr-2007	7,632,862
12/610,843	02-Nov-2009	
12/409,111	23-Mar-2009	7,769,575
15/430,100	10-Feb-2017	9,926,367
60/790,506	07-Apr-2006	
60/798,896	09-May-2006	
11/784,094	05-Apr-2007	7,973,142
15/894,442	12-Feb-2018	
13/115,180	25-May-2011	8,524,235
13/958,990	05-Aug-2013	
60/816,730	27-Jun-2006	
60/816,731	27-Jun-2006	
60/816,825	27-Jun-2006	
11/823,086	26-Jun-2007	7,622,593
11/821,846	26-Jun-2007	7,795,444
11/821,868	26-Jun-2007	7,589,212
12/624,072	23-Nov-2009	8,258,311
13/309,452	01-Dec-2011	8,338,615
13/691,757	01-Dec-2012	8,946,232
13/936,450	08-Jul-2013	8,895,563
13/309,445	01-Dec-2011	8,329,916
14/569,106	12-Dec-2014	9,126,958
14/252,140	14-Apr-2014	9,284,285
15/016,599	05-Feb-2016	9,795,594
15/705,639	15-Sep-2017	
12/558,169	11-Sep-2009	
12/850,026	04-Aug-2010	8,106,078
12/467,430	18-May-2009	8,188,125
13/626,614	25-Sep-2012	8,846,685
61/144,022	12-Jan-2009	
61/184,986	08-Jun-2009	
12/677,512	22-Mar-2010	
14/075,809	08-Nov-2013	
15/443,353	27-Feb-2017	
13/968,269	15-Aug-2013	
13/724,396	21-Dec-2012	9,096,555
61/223,260	06-Jul-2009	
13/783,311	03-Mar-2013	8,883,832
14/272,689	08-May-2014	9,174,950
14/864,462	24-Sep-2015	9,949,956
12/677,550	01-Dec-2010	8,569,348
15/913,392	06-Mar-2018	
15/796,293	27-Oct-2017	
61/390,899	07-Oct-2010	
13/253,397	05-Oct-2011	

14/300,385	10-Jun-2014	
15/462,326	17-Mar-2017	
61/546,708	13-Oct-2011	
13/652,154	15-Oct-2012	8,999,325
14/627,463	20-Feb-2015	
15/463,340	20-Mar-2017	10,329,357
15/438,218	21-Feb-2017	10,150,811
61/546,697	13-Oct-2011	
61/546,748	13-Oct-2011	
13/652,203	15-Oct-2012	
16/168,060	23-Oct-2018	
61/792,679	15-Mar-2013	
61/792,868	15-Mar-2013	
61/882,048	25-Sep-2013	
61/882,056	25-Sep-2013	
61/934,570	31-Jan-2014	
13/999,670	14-Mar-2014	9,440,963
14/214,413	14-Mar-2014	
15/099,161	14-Apr-2016	
15/355,910	18-Nov-2016	10,220,048
15/443,622	27-Feb-2017	
15/098,955	14-Apr-2016	
15/958,346	20-Apr-2018	
15/958,355	20-Apr-2018	
15/958,358	20-Apr-2018	
15/969,109	02-May-2018	
16/257,287	25-Jan-2019	
61/953,680	14-Mar-2014	
14/657,276	13-Mar-2015	9,994,560
15/972,863	07-May-2018	
14/819,871	06-Aug-2015	9,539,245
15/365,186	30-Nov-2016	
62/034,695	07-Aug-2014	
62/190,871	10-Jul-2015	
62/019,002	30-Jun-2014	
62/361,703	13-Jul-2016	
62/054,752	24-Sep-2014	
14/862,948	23-Sep-2015	
15/815,097	16-Nov-2017	
62/222,481	23-Sep-2015	
15/273,068	22-Sep-2016	
62/364,381	20-Jul-2016	
62/377,072	19-Aug-2016	
15/654,289	19-Jul-2017	10,253,094
16/180,850	05-Nov-2018	
16/180,854	05-Nov-2018	
62/635,102	26-Feb-2018	
62/790,646	10-Jan-2019	
16/284,349	25-Feb-2019	